Compare Aehr Test Systems (AEHR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Novo Nordisk A/S — how do they compare? Aehr Test Systems trades at $129 (market cap $3.82B), while Novo Nordisk A/S trades at $46.49 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 54.4× Aehr Test Systems's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | NVO | |
|---|---|---|
Market Cap | $3.82B | $207.85B |
Sector | Technology | Health |
52-Week High | $117.18 | $63.98 |
52-Week Low | $17.38 | $35.29 |
Enterprise Value | $3.72B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aehr Test Systems (AEHR) trades at $129.23, up 21.69% in the last 24 hours, reflecting strong momentum. The stock is technically bullish, trading near resistance at $129, with a high RSI suggesting potential overbought conditions. Fundamentally, the company reported a net loss of $3.91 million for 2025, but has beaten EPS estimates for three consecutive quarters. Recent news highlights a $22 million follow-on order for AI processor wafer-level burn-in systems, signaling robust demand in high-growth sectors.
The outlook is supported by record bookings and a strategic pivot to AI infrastructure, though high valuation multiples and insider selling pose risks. Revenue growth guidance of 160-200% for FY27 offers significant upside potential, but investor caution is warranted due to customer concentration and current unprofitability.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
